90 results
8-K
EX-99.1
PULM
Pulmatrix, Inc.
13 Aug 24
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
9:05am
winding down of the PUR1900 Phase 2b clinical trial, for which the Company incurred fewer expenses eligible for reimbursement under its Agreement
DEFA14A
EX-10.1
l63fc
15 Dec 21
Additional proxy soliciting materials
5:27pm
8-K
EX-10.1
9n7piwunxbw8u gwy
15 Dec 21
Pulmatrix Announces $6.75 Million Registered Direct Offering
5:27pm